DRA Consulting is now PharmaLex Finland
As we are merging with the global service provider PharmaLex, our name has been changed to PharmaLex Finland.
Author: dra-updater
Posts by dra-updater
Biological medicines: how does their manufacturing process differ from traditional medicines?
The differences in the manufacturing process and the nature of the active substance itself mean that biologicals differ from traditional medicines in many ways.
EU Council to postpone the MDR deadlines
The commission’s plan would not automatically apply an extended transitional period for all the medical devices, but the extension would be allowed on the condition that it is critical for the safety of the patients.
Our team of great colleagues has grown again
We are proud to introduce our new team of experts
This Christmas we give gifts to the Baltic Sea
With our Christmas donation, we support the activities of the John Nurminen Foundation to save the Baltic Sea and its heritage.
Crisis-tolerant security of medicine supply
DRA Consulting has conducted an extensive preliminary report on the operating environment of the medicine supply chain, commissioned by the healthcare pool that operates under the National Emergency Supply Agency.
New COVID‑19 vaccine swiftly launched to the market in tight timeline
Company prepared the launch of vaccine in extremely tight timeline. They needed help to prepare linguistically and medically correct product information texts in extremely tight timeline.
Market Access Expert, Nordic Market Access team
Our Nordic Market Access team is growing, and we are looking for an additional team member to join us in Finland.
From an independent company to part of PharmaLex Group – how it all happened
When a company reaches a certain size and a certain level of maturity, the investors and other industry operators start to show interest. That is what happened to us too.
Our expert team grows
DRA’s expert team grows even stronger. We are pleased to announce the addition of new top talents to our ranks.
Success in medicinal product dossier preparation for global markets
When developing a new medicinal product, our client opted for a global approach: they wanted to access all the major markets, and to benefit from synergy, they decided to prepare the CMC documentation for the EU, FDA and Japan authorities simultaneously.
Use the promotion code DRA20 for the trainings organised by the Finnish Pharmaceutical Information Centre
In celebration of DRA’s 20th anniversary, we can now offer a 20 % discount on the regular price of the trainings to our clients and partners.
Our growth story continues – DRA Consulting to become part of the PharmaLex Group
DRA and PharmaLex are merging to create a centre of pharma and Health Tech expertise with nearly 3,000 experts. The merger will bring synergies for the customers of both companies while helping to accelerate Nordic cooperation in the pharmaceutical market.
Press Release: PharmaLex expands Nordic footprint across key business units with DRA Consulting merger
PharmaLex expands Nordic footprint across key business units with DRA Consulting merger
Cooperation will make the Nordic region an attractive pharmaceutical market
In the global pharmaceutical market, the individual Nordic countries are very small. Together, they are much larger, but still relatively lightweight. This is certainly true if you look purely at sales volumes.
A sneak peek to the future: ÄLY seminar puts the spotlight on finnish innovations and solutions for sustainable drug development
In this year’s ÄLY seminar organised by DRA, the discussion turned around different future visions about green pharmacy, corporate social responsibility, the latest innovations in health technology and the possibilities that quantum technology can offer for drug development.
DADI webinar: What will happen at go-live
The first web-based form to be released in the DADI project is a variations form for human medicinal products, and it is still expected to go live in October 2022.
There is strength in numbers – DRA crowdsources visioning of the future
Last year, we engaged all of our 100-plus employees in the organisation’s strategy work and visioning the future. This way, we managed to harness the silent knowledge of all our employees for the company’s foresight process, and by crowdsourcing, we also future-proofed our strategy.
Three new guidance documents related to IVD medical devices available
Three guidance documents regarding in vitro diagnostic medical devices were published in May by the Medical Devices Coordination Group (MDCG).
New experts to join DRA – call for more talents still ongoing
DRA keeps growing! Warmly welcome Virve and Maura.
Is it a drug or a device? A useful guidance document on borderline products available
The Medical Device Coordination Group (MDCG) has provided guidance on how to better identify the borderline between a medical device and a drug.
One month till the new dawn – EU IVDR will be applied in full in May 2022
In this blog post, our Health Tech Team Leader Tiina Riihimäki provides an overview of the latest developments and the foreseeable challenges in the process. Read her expert advice on how to prepare for this historic legislative change.
DRA Driving Responsible Action
What does responsibility mean to you? What would you set as your goal for social responsibility in 2022? These are some of the questions that all DRA’s employees were asked in the beginning of this year.